The Vaccine BookBarry R. Bloom, Paul-Henri Lambert Academic Press, 2003 - 436 páginas A definitive and readable reference guide to the world of vaccines! The Vaccine Book provides concrete information on the current and future world of vaccines. It reveals the scientific opportunities and potential impact of vaccines, including economic and ethical challenges, problems encountered when producing vaccines, how clinical vaccine trials are designed, and how to introduce vaccines into widespread use. Although vaccines are now available for many diseases, there are still challenges ahead for major diseases such as AIDS, tuberculosis, and malaria. The Vaccine Book is designed to increase the understanding of vaccines for students, researchers, public health officials, and all others working to address such challenges. Topics unique to this book: * Ethics * Economics * Diseases that could be prevented * Clinical trial designs * Ideas about the future of vaccines * Challenges facing research scientists in the vaccine area * Burden of vaccine-preventable illness and the impact of vaccines * Scientific obstacles to be overcome by existing and new vaccines * Basic mechanisms of host immunity and pathogen interaction with host tissues * New approaches to future vaccines against challenging diseases * Real and perceived safety issues which dominate vaccine development and vaccination policies * Microbial pathogenesis as a basis for vaccine design * Planning vaccine trials * Introducing new vaccines into the healthcare system * Future challenges for vaccines and immunizations |
Dentro del libro
Página viii
Barry R. Bloom, Paul-Henri Lambert. VI. New Era of Challenges and Opportunities in Vaccinology 13 VII. The Quest for Vaccines against the “Big Three” 14 A. HIV—AIDS 15 B. Malaria 15 C. Tuberculosis 16 D. Summary 16 VIII. Conclusion 16 ...
Barry R. Bloom, Paul-Henri Lambert. VI. New Era of Challenges and Opportunities in Vaccinology 13 VII. The Quest for Vaccines against the “Big Three” 14 A. HIV—AIDS 15 B. Malaria 15 C. Tuberculosis 16 D. Summary 16 VIII. Conclusion 16 ...
Página x
... Challenge of Improving Early Life Antibody Responses 75 III. Early Life T-Cell Responses 76 A. Characteristics of Early Life T-Cell Responses 76 B. Factors That Limit Early Life T-Cell Responses 77 C. Can Early Life Immunization Induce ...
... Challenge of Improving Early Life Antibody Responses 75 III. Early Life T-Cell Responses 76 A. Characteristics of Early Life T-Cell Responses 76 B. Factors That Limit Early Life T-Cell Responses 77 C. Can Early Life Immunization Induce ...
Página xiii
... 184 Route of Administration 184 G. New Targets 184 Challenges Facing Use of Vaccines 185 A. Safety 185 B. Vaccine Cost 186 C. Vaccine Production 186 References 187 i'11P1UO§7¢" B Polio CIRO A. DE QUADROS I. Introduction 189 II. CONTENTS.
... 184 Route of Administration 184 G. New Targets 184 Challenges Facing Use of Vaccines 185 A. Safety 185 B. Vaccine Cost 186 C. Vaccine Production 186 References 187 i'11P1UO§7¢" B Polio CIRO A. DE QUADROS I. Introduction 189 II. CONTENTS.
Página xv
... Challenges to Rotavirus Vaccine Development and Introduction 237 A. Ensuring Vaccine Safety: Intussusception 23 7 B. Differences hetu/een Rotavirus in Developed and Developing Country Settings and Impact on Vaccine Development 23 9 C ...
... Challenges to Rotavirus Vaccine Development and Introduction 237 A. Ensuring Vaccine Safety: Intussusception 23 7 B. Differences hetu/een Rotavirus in Developed and Developing Country Settings and Impact on Vaccine Development 23 9 C ...
Página xvi
Barry R. Bloom, Paul-Henri Lambert. F. AIDS. Vaccines: Challenges. and. Prospects. ELISA I. CHOI AND NORMAN L. LETVIN I. II. III. IV. V. VI. VII. VIII Introduction 245 The Burden of HIV—AIDS 245 Biology of HIV 246 Immune Control of HIV 247 ...
Barry R. Bloom, Paul-Henri Lambert. F. AIDS. Vaccines: Challenges. and. Prospects. ELISA I. CHOI AND NORMAN L. LETVIN I. II. III. IV. V. VI. VII. VIII Introduction 245 The Burden of HIV—AIDS 245 Biology of HIV 246 Immune Control of HIV 247 ...
Contenido
CHAPTER 1 GLOBAL BURDEN OF DISEASE | 1 |
CHAPTER 2 IMMUNOLOGY | 51 |
CHAPTER 3 TRIAL DESIGN FOR VACCINES | 85 |
CHAPTER 4 ETHICS AND VACCINES | 119 |
CHAPTER 5 UNDERSTANDING MICROBIAL PATHOGENESIS AS A BASIS FOR VACCINE DESIGN | 129 |
Selected Cases | 179 |
Otras ediciones - Ver todas
Términos y frases comunes
activation adjuvants adults adverse events agents antibody antibody responses antigens attenuated bacterial benefits cancer CD4+ T cells CD8+ cellular challenge clinical trials cost cost-effectiveness coverage cytokines cytotoxic defined developing countries difficult DNA vaccines doses effective effector efficacy efficient Epidemiol epidemiology epitopes eradication evaluation falciparum field first genes genome global Haemophilus influenzae Helicobacter pylori hepatitis HIV vaccine host cell human identified immune response immunization programs immunogenicity Immunol immunological incidence individuals induce infants infectious diseases intussusception major malaria vaccine measles memory meningococcal mice neonatal parasite pathogens Pediatr peptide pertussis vaccines Plasmodium falciparum pneumococcal conjugate vaccine polio poliovirus polysaccharide population potential prevent production protein pylori receptor recombinant risk rotavirus vaccine rubella vaccine scientific serotypes significant specific strains strategies Streptococcus pneumoniae studies sufficient surveillance T-cell T-cell responses target infection tion transmission tuberculosis vaccine development viral virus viruses World Health Organization